◆ mixed
Impact
PhaseFiled/PDUFA (NDA submitted)
Time to marketIf the FDA accepts the NDA for filing, a standard review would take 10 months from filing acceptance, with a potential PDUFA date in late 2027. Priority review (if granted) could shorten this to 6-8 months. The FDA has 60 days from the October 28 submission to decide on filing acceptance.
remibetadex Updated Oct 29
What to watch
The next catalyst is the FDA's filing decision within approximately 60 days (by late December 2026). If the NDA is accepted, a PDUFA target action date will be assigned. If rejected, the stock could face significant downside given the Phase 3 primary endpoint miss. Watch for any financing announcements given the $22.1M cash balance and ongoing burn rate.
Bull case
- Statistically significant benefit in the prespecified subgroup (p=0.046) covering ~83% of the trial population provides a regulatory path forward
- Overall survival analysis showed 85% mortality risk reduction (p=0.044), a compelling efficacy signal in a fatal disease with no prior approved therapies until 2024
- Orphan Drug, Fast Track and Rare Pediatric Disease designations provide regulatory incentives and potential Priority Review Voucher eligibility upon approval
Bear case
- Phase 3 trial missed the primary endpoint in the overall population (p=0.19), a significant hurdle for FDA approval that may require additional trials
- Two FDA-approved NPC therapies already exist (Miplyffa/arimoclomol and Aqneursa/levacetylleucine, both approved September 2024), creating a competitive landscape that did not exist when remibetadex trials began
- Serious adverse events were more than double in the treatment arm (35.9%) versus placebo (16.7%), raising safety concerns